Clinical trials: Venous Thromboembolic Event
Venous Thromboembolism
Toronto Thromboprophylaxis Patient Safety Initiative
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE, is one of the common and preventable complications of hospital stay.
- Trial name
- TOPPS (NCT01869075)
- Testing
- Knowledge Translation (KT) toolkit
- Where
- Canada
- Volunteers
- 1,895 people
- Sponsor
- Sunnybrook Health Sciences Centre
Venous Thromboembolism, Risk Assessment
Multiple Algorithms System Of All Scores in Embolism (MOSE)
The aim of this study is to overcome the current limits of the scoring systems used to predict both the thrombotic (VTE) and hemorrhagic (BLD) risk for the patient.
- Conditions
- Venous Thromboembolism, Risk Assessment, Risk Management
- Trial name
- MOSE (NCT02911012)
- Where
- 2 sites in Italy
- Volunteers
- 15,208 people, healthy volunteers welcome
- Sponsor
- University Magna Graecia
Pulmonary Embolism
Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China
EINSTEIN PE study demonstrated that rivaroxaban is at least as effective as the current standard therapy with 51% relative risk reduction of major bleeding (1.1% vs.
- Trial name
- XAPEC (NCT03410706)
- Testing
- Rivaroxaban(Xarelto, BAY 59-7939)
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Bayer
Venous Thromboembolism, Esophagus Cancer
Venous Thromboembolism and Bleeding Risk in Patients With Esophageal Cancer
This study aims to assess the 6- and 12-month venous thromboembolism (VTE) and bleeding incidence from the start of cancer diagnosis in a retrospective cohort of patients with esophageal cancer.
- Conditions
- Venous Thromboembolism, Esophagus Cancer, Bleeding, Chemotherapy Effect
- Trial name
- VENETIA (NCT03646409)
- Testing
- Venous thromboembolic event, arterial thromboembolic event, bleeding events
- Where
- Netherlands
- Volunteers
- 542 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Cardiac Arrhythmias, Hemorrhage
Tapered Warfarin or Interrupted Warfarin With Heparin Bridging for Pacemaker or Defibrillator Implantation
Approximately 2 million patients in North America are currently treated with the blood thinner warfarin. These patients have every year more than 200,000 invasive procedures, for which warfarin must be stopped to avoid bleeding…
- Conditions
- Cardiac Arrhythmias, Hemorrhage, Thromboembolism
- Trial name
- PACEBRIDGE (NCT02094157)
- Testing
- Tapered warfarin regimen, Bridged regimen Low-molecular-weight heparin
- Where
- 2 sites in Canada
- Volunteers
- 173 people
- Sponsor
- McMaster University
Vagina Atrophy
Vaginal Estrogen Treatment and Effect on Hemostatic Parameters in Postmenopausal Women
This study investigates whether vaginal estrogen treatment has an effect on hemostatic parameters in postmenopausal women. Blood samples are collected before and after 3 months treatment to assess changes in hemostasis.
- Trial name
- NCT07160504
- Testing
- Vaginal estradiol tablets
- Where
- Denmark
- Volunteers
- 90 people
- Sponsor
- University of Aarhus
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
The primary objective is to compare the efficacy and safety of once daily (q.d.) subcutaneous (s.c.) injections of Semuloparin sodium (AVE5026) with q.d. s.c.
- Trial name
- SAVE-ABDO (NCT00679588)
- Testing
- Semuloparin Sodium, Enoxaparin sodium
- Where
- 270 sites in United States, Argentina and 37 more
- Volunteers
- 4,413 people
- Sponsor
- Sanofi
Venous Thromboembolism
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
The primary efficacy objective is to evaluate whether dabigatran etexilate is superior to placebo in the long-term prevention of recurrent symptomatic venous thrombo-embolism (VTE) in patients with symptomatic deep-vein…
- Trial name
- RE-SONATE (NCT00558259)
- Testing
- dabigatran etexilate 150 mg twice daily (BID)
- Where
- 147 sites in United States, Australia and 19 more
- Volunteers
- 1,353 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
Long-term Surveillance of Patients With Venous Thromboembolism: a Nationwide Prospective Cohort Study
This observational study aims to establish a prospective nationwide cohort of venous thromboembolism. The main questions it mains to answer are: Which patients with venous thromboembolism should accept long-term anticoagulation…
- Trial name
- NCT06073366
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- China National Center for Cardiovascular Diseases
Cancer-related Venous Thromboembolism
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
The goal of this research study is to learn about the quality of life, experiences with treatment, and healthcare costs of patients who are receiving long-term treatment for venous thromboembolism (VTE) that is related to cancer.
- Trial name
- NCT03407469
- Testing
- Questionnaires
- Where
- 4 sites in United States, Colombia and 1 more
- Volunteers
- 260 people
- Sponsor
- M.D. Anderson Cancer Center
Venous Thromboembolic Disease, Respiratory Disease
Screening for Cancer in Patients With Unprovoked VTE
Open and multicenter randomized clinical trial (1:1) comparing limited screening with extended screening with the performance of Positron emission tomography-computed tomography (PET-CT) scan in the search for neoplasms in…
- Conditions
- Venous Thromboembolic Disease, Respiratory Disease, Pulmonary Disease, Deep Venous Thrombosis
- Trial name
- SOME-RIETE (NCT03937583)
- Testing
- Fludeoxyglucose 18F
- Where
- 17 sites in Spain
- Volunteers
- 650 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Colorectal Surgery, VTE (Venous Thromboembolism)
A Multicenter, Open-Label, Non-Inferiority Randomized Controlled Trial of Postoperative VTE Prevention in Chinese Patients After Colorectal Cancer Surgery
research objective 1. Optimize VTE prevention management after CRC surgery. 2. Improve the prevention and treatment level of VTE in current perioperative patients. 3. Reduce the social burden of VTE related diseases.
- Trial name
- NCT06583330
- Testing
- Low Molecular Weight Heparin (dalteparin)
- Volunteers
- 1,448 people
- Sponsor
- Beijing Friendship Hospital
Venous Thromboembolism
Graduated Compression Stockings (GCS) Pilot Substudy
This is a pilot substudy to the PeriOperative ISchemic Evaluation-2 Trial (POISE-2), to assess the feasibility of adding graduated compression stockings (GCS) to POISE-2 as an intervention.
- Trial name
- NCT01234064
- Testing
- Anti-Embolism Graduated Pressure Stockings (by BSN-Jobst), No Graduated Compression Stockings
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Hamilton Health Sciences Corporation
Venous Thromboembolism, Deep-Vein Thrombosis
Pro-coagulant Markers and Anticoagulant Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism
The presence of clots in the veins of arms and/or legs or lungs of Cancer patients decreases their quality of life, delays their treatment and may cause death.
- Conditions
- Venous Thromboembolism, Deep-Vein Thrombosis, Pulmonary Embolism, Cancer
- Trial name
- REMARK (NCT01602445)
- Where
- 5 sites in Canada
- Volunteers
- 700 people
- Sponsor
- Ottawa Hospital Research Institute
Venous Thromboembolism, Cancer
Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
This trial seeks to evaluate a management strategy after the acute treatment duration (≥ 3 months of therapeutic anticoagulation) for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT).
- Conditions
- Venous Thromboembolism, Cancer, Upper Extremity Deep Vein Thrombosis, Catheter-Related Infections
- Trial name
- STREAM-Line (NCT06603870)
- Testing
- Anticoagulation Therapy
- Where
- 2 sites in Canada
- Volunteers
- 330 people
- Sponsor
- Ottawa Hospital Research Institute
Venous Thromboembolism
D-dimer to Predict Recurrence in Patients With Multiple Episodes of Venous Thromboembolism
Optimal duration of oral anticoagulant therapy in patients with recurrent episodes of venous thromboembolism (VTE) is a matter of debate and recommendations are based on inadequate evidence.
- Trial name
- NCT00428441
- Testing
- Warfarin
- Where
- Italy
- Volunteers
- 73 people
- Sponsor
- Università degli Studi dell'Insubria
Venous Thromboembolism, Deep Vein Thrombosis (DVT)
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism
- Trial name
- NCT00986154
- Testing
- edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
- Where
- 454 sites in United States, Argentina and 36 more
- Volunteers
- 8,292 people
- Sponsor
- Daiichi Sankyo
Thromboembolism
Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)
The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin Pro re nata (As needed/PRN) to maintain an International Normalised Ratio (INR)…
- Trial name
- RE-COVER II (NCT00680186)
- Testing
- Warfarin, Dabigatran etexilate
- Where
- 220 sites in United States, Australia and 29 more
- Volunteers
- 2,589 people
- Sponsor
- Boehringer Ingelheim
Prevention, Venous Thromboembolism
Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and can help prevent blood clots forming after a hip replacement operation.
- Trial name
- RECORD 2 (NCT00332020)
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 126 sites in United States, Australia and 21 more
- Volunteers
- 2,457 people
- Sponsor
- Bayer
Deep Vein Thrombosis
Understanding Risk Factors Involved in Developing a Second Blood Clot.
The purpose of this study is to develop a way to predict which patients diagnosed with idiopathic blood clots can safely stop warfarin therapy after six months.
- Trial name
- NCT00261014
- Where
- 7 sites in Canada, France
- Volunteers
- 800 people
- Sponsor
- Ottawa Hospital Research Institute